Halo Labs
Low Volume High-Throughput Cell, Gene, and Protein Therapeutic Quality
Low Volume High-Throughput Cell, Gene, and Protein Therapeutic Quality
Halo Labs is a United States-based startup specializing in enabling its clients to reduce development time and enhance patient safety in the field of protein therapeutics and cell and gene therapy products. Their flagship product Aura utilizes cutting-edge optics and advanced algorithms to analyze and identify sub-visible and visible particles, such as protein, viral capsid, and cell aggregates, offering high-throughput and low-volume particle analysis in a wide range of samples. Founded in 2011, the company operates in the Analytics, Biopharma, Biotechnology, and Pharmaceutical industries. It recently secured a $7.00M Series C investment on 11 July 2022, with funding from BioAdvance, BroadOak Capital Partners, RCT, and Agilent Technologies. Halo Labs' commitment to advancing the quality and efficiency of cell, gene, and protein therapeutics marks it as a promising venture for potential investors and industry stakeholders.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Series C | $7.00M | 4 |
|
11 Jul 2022 |
| Series B | $12.00M | 4 |
|
06 Apr 2020 |
| Series B | $5.60M | 4 |
|
20 Dec 2018 |
| Seed Round | $75.00K | 1 |
|
06 May 2015 |
| Seed Round | Unknown | 1 |
|
13 Jun 2014 |
No recent news or press coverage available for Halo Labs.
-logo.jpg){kind=logo}
We care about your data, and we'd love to use cookies make your experience better.
